ALNY
AlnylamBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull: Positive late‑stage readouts, sustained AMVUTTRA uptake, and favorable formulary placements drive above‑consensus revenue and multiple expansion, supporting the bull target of 595.875 within the scenario horizon.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.2.
What can break
Clinical trial failures or delays
Momentum
19
Value
58
Sentiment
95
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $397.25 · Bull $595.88 · Bear $238.35
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-31 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $463.13
Why
Momentum19 · Δ7d +3.4
Value58 · Δ7d +0.2
Sentiment95 · Δ7d +5.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
19
34% active weight
Current posture
7d trendSoftening
Δ7d
+3.4
Δ21d
+9.7
Value
58
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.4
Sentiment
95
33% active weight
Current posture
7d trendImproving
Δ7d
+5.2
Δ21d
+4.8
Why this grade
Composite grade B. Momentum 18.6 / Value 58.0 / Sentiment 94.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$39.47B
Beta
0.35
Shares Out
132.11M
P/E (TTM)
1738.9
P/S (TTM)
16.37
P/FCF (TTM)
237.43
Rev YoY
+149.3%
EPS YoY
+310.7%
Gross Margin
+83.9%
Op Margin
+7.0%
Net Debt
-$222.51M
Current Ratio
2.54
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology